{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:45:15Z","timestamp":1773294315422,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00120-026-02781-z","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T18:35:54Z","timestamp":1770662154000},"page":"250-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie des nicht-muskelinvasiven Blasenkarzinoms","Treatment of non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"65","author":[{"given":"Mirjam","family":"Leeder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2781_CR1","unstructured":"Robert Koch Institut und Zentrum f\u00fcr Krebsregisterdaten (2022) Krebs in Deutschland - Harnblasenkrebs. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Harnblasenkrebs\/harnblasenkrebs_node.html. Accessed 15.12.2025"},{"issue":"3","key":"2781_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester\u00a0RJ et\u00a0al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013475","journal-title":"Eur Urol"},{"key":"2781_CR3","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K. and AWMF).  S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 3.0, 2025, AWMF-Registernummer: 032- 038OL. 2025 [cited 2025 15.12.]; Available from: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom\/."},{"issue":"5","key":"2781_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","volume":"57","author":"P Mariappan","year":"2010","unstructured":"Mariappan\u00a0P, Zachou\u00a0A, Grigor\u00a0KM (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a\u00a0surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57(5):843\u2013849","journal-title":"Eur Urol"},{"issue":"1","key":"2781_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk\u00a0M et\u00a0al (2022) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 81(1):75\u201394","journal-title":"Eur Urol"},{"issue":"2","key":"2781_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/cas.15193","volume":"113","author":"K Inoue","year":"2022","unstructured":"Inoue\u00a0K et\u00a0al (2022) Current status of photodynamic technology for urothelial cancer. Cancer Sci 113(2):392\u2013398","journal-title":"Cancer Sci"},{"issue":"5","key":"2781_CR7","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez\u00a0J et\u00a0al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J\u00a0Urol 182(5):2195\u20132203","journal-title":"J Urol"},{"issue":"1","key":"2781_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier\u00a0S et\u00a0al (2016) EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1\u20113 Years of Maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol 69(1):60\u201369","journal-title":"Eur Urol"},{"issue":"4","key":"2781_CR9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester\u00a0RJ et\u00a0al (2021) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol 79(4):480\u2013488","journal-title":"Eur Urol"},{"issue":"1","key":"2781_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo\u00a0N et\u00a0al (2022) Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin. Eur Urol Oncol 5(1):84\u201391","journal-title":"Eur Urol Oncol"},{"key":"2781_CR11","unstructured":"Gontero P et\u00a0al (2025) EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer. Accessed 15.12.2025"},{"issue":"2","key":"2781_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester\u00a0RJ et\u00a0al (2016) Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder Which Patients Benefit from the Instillation. Eur Urol 69(2):231\u201344","journal-title":"Eur Urol"},{"issue":"2","key":"2781_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m\u00a0PU et\u00a0al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"issue":"4","key":"2781_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"A B\u00f6hle","year":"2004","unstructured":"B\u00f6hle\u00a0A, Bock\u00a0PR (2004) Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682\u20136","journal-title":"Urology"},{"issue":"1","key":"2781_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle\u00a0A, Jocham\u00a0D, Bock\u00a0PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J\u00a0Urol 169(1):90\u201395","journal-title":"J Urol"},{"issue":"3","key":"2781_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens\u00a0J et\u00a0al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63(3):462\u201372","journal-title":"Eur Urol"},{"key":"2781_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.euros.2023.08.004","volume":"56","author":"C van Straten","year":"2023","unstructured":"van Straten\u00a0C et\u00a0al (2023) Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Gu\u00e9rin Instillations: The EAU-RF NIMBUS Trial. Eur Urol Open Sci 56:15\u201324","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"2781_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"MO Grimm","year":"2020","unstructured":"Grimm\u00a0MO et\u00a0al (2020) Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial \u201cNIMBUS\u201d. Eur Urol 78(5):690\u2013698","journal-title":"Eur Urol"},{"issue":"2","key":"2781_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","volume":"68","author":"L Mart\u00ednez-Pi\u00f1eiro","year":"2015","unstructured":"Mart\u00ednez-Pi\u00f1eiro\u00a0L et\u00a0al (2015) Maintenance Therapy with 3\u2011monthly Bacillus Calmette-Gu\u00e9rin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol 68(2):256\u2013262","journal-title":"Eur Urol"},{"issue":"4","key":"2781_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/bju.13146","volume":"117","author":"M Moschini","year":"2016","unstructured":"Moschini\u00a0M et\u00a0al (2016) Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int 117(4):604\u2013610","journal-title":"BJU Int"},{"key":"2781_CR21","doi-asserted-by":"crossref","unstructured":"Diamant, E., et\u00a0al., Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer. Cancers (Basel), 2022. 14(15).","DOI":"10.3390\/cancers14153797"},{"issue":"10516","key":"2781_CR22","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","volume":"406","author":"M De Santis","year":"2025","unstructured":"De Santis\u00a0M et\u00a0al (2025) Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 406(10516):2221\u20132234","journal-title":"Lancet"},{"issue":"8","key":"2781_CR23","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","volume":"31","author":"ND Shore","year":"2025","unstructured":"Shore\u00a0ND et\u00a0al (2025) Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial. Nat Med 31(8):2806\u20132814","journal-title":"Nat Med"},{"key":"2781_CR24","doi-asserted-by":"crossref","unstructured":"Roupret, M., et\u00a0al., ALBAN (GETUG-AFU 37): a\u00a0phase\u00a0III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol, 2025.","DOI":"10.1016\/j.annonc.2026.01.017"},{"issue":"10","key":"2781_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fon-2019-0817","volume":"16","author":"AM Kamat","year":"2020","unstructured":"Kamat\u00a0AM et\u00a0al (2020) KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC. Future Oncol 16(10):507\u2013516","journal-title":"Future Oncol"},{"key":"2781_CR26","unstructured":"clinicaltrials.gov (National Library of Medicina des National Center for Biotechnology Information). Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676\/KEYNOTE-676). [cited 2025 15.12.]; Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03711032."},{"issue":"6 Pt B","key":"2781_CR27","first-page":"E216","volume":"110","author":"H Shirakawa","year":"2012","unstructured":"Shirakawa\u00a0H et\u00a0al (2012) Prognostic significance of Bacillus Calmette-Gu\u00e9rin failure classification in non-muscle-invasive bladder cancer. BJU Int 110(6 Pt B):E216\u2013E221","journal-title":"BJU Int"},{"issue":"4","key":"2781_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043266","volume":"11","author":"SL Maibom","year":"2021","unstructured":"Maibom\u00a0SL et\u00a0al (2021) Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open 11(4):e043266","journal-title":"BMJ Open"},{"key":"2781_CR29","unstructured":"Food and Drug Administration. Highlight of the Prescribing Information for Keytruda\u00ae (Pembrolizumab). [cited 2025 19.12.]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125514s172lbl.pdf."},{"issue":"7","key":"2781_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar\u00a0AV et\u00a0al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22(7):919\u2013930","journal-title":"Lancet Oncol"},{"issue":"6","key":"2781_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi\u00a0A et\u00a0al (2024) Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol 25(6):720\u2013730","journal-title":"Lancet Oncol"},{"issue":"1","key":"2781_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/JU.0000000000004020","volume":"212","author":"VM Narayan","year":"2024","unstructured":"Narayan\u00a0VM et\u00a0al (2024) Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5\u2011Year Follow-Up From a Phase 3 Trial. J\u00a0Urol 212(1):74\u201386","journal-title":"J Urol"},{"issue":"1","key":"2781_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie\u00a0K et\u00a0al (2023) IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. NEJM Evid 2(1):EVIDoa2200167","journal-title":"NEJM Evid"},{"issue":"33","key":"2781_CR34","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1200\/JCO-25-01651","volume":"43","author":"S Daneshmand","year":"2025","unstructured":"Daneshmand\u00a0S et\u00a0al (2025) TAR-200 for Bacillus Calmette-Gu\u00e9rin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe\u20111 Study. J\u00a0Clin Oncol 43(33):3578\u20133588","journal-title":"J Clin Oncol"},{"key":"2781_CR35","unstructured":"Food and Drug Administration. Highlight of the Prescribing Information for Adstiladrin\u00ae (Nadofaragene Firadenovec). [cited 2025 19.12.]; Available from: https:\/\/www.fda.gov\/media\/164029\/download?attachment."},{"issue":"1","key":"2781_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian\u00a0SA et\u00a0al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107\u2013117","journal-title":"Lancet Oncol"},{"key":"2781_CR37","unstructured":"Food and Drug Administration. Highlight of the Prescribing Information for Anktiva\u00ae (Nogapendekin alfa inbakicept). [cited 2025 19.12.]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761336s000lbl.pdf."},{"key":"2781_CR38","unstructured":"Food and Drug Administration. Highlight of the Prescribing Information for Inlexzo\u00ae (Gemcitabine Intravesical System). [cited 2025 19.12.]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219683s000lbl.pdf."},{"issue":"1","key":"2781_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles\u00a0MA, Hurst\u00a0CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25\u201341","journal-title":"Nat Rev Cancer"},{"key":"2781_CR40","unstructured":"Food and Drug Administration. FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma. [cited 2026 06.01.]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma."},{"issue":"1","key":"2781_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"Catto\u00a0JWF et\u00a0al (2024) Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann Oncol 35(1):98\u2013106","journal-title":"Ann Oncol"},{"key":"2781_CR42","unstructured":"Tyson, M., et\u00a0al., Pivotal Results from BOND-003: A Phase\u20113, Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of BCG Unresponsive, High-Risk, NMIBC with CIS, in AUA Annual Meeting. 2025: San Antonio, TX, USA."},{"key":"2781_CR43","unstructured":"clinicaltrials.gov (National Library of Medicina des National Center for Biotechnology Information). Phase\u00a02\u00a0Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC. [cited 2025 18.12.]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06567743."},{"key":"2781_CR44","unstructured":"clinicaltrials.gov (National Library of Medicina des National Center for Biotechnology Information). A\u00a0Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in Participants With BCG-na\u00efve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3). [cited 2025 15.12.]; Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05714202."},{"key":"2781_CR45","unstructured":"clinicaltrials.gov (National Library of Medicina des National Center for Biotechnology Information). A\u00a0Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1). [cited 2025 18.12.]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT06319820."},{"issue":"4","key":"2781_CR46","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates\u00a0M et\u00a0al (2020) Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res 26(4):882\u2013891","journal-title":"Clin Cancer Res"},{"key":"2781_CR47","unstructured":"clinicaltrials.gov (National Library of Medicina des National Center for Biotechnology Information). A\u00a0Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011\/INTerpath-011). [cited 2025 15.12.]; Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06833073."}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02781-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02781-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:50:40Z","timestamp":1773233440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02781-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2781"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02781-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Leeder, K.\u00a0Leucht, M.\u00a0Marx und M.-O.\u00a0Grimm geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}